238 related articles for article (PubMed ID: 83969)
1. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes.
Schirrmacher V; Bosslet K; Shantz G; Clauer K; Hübsch D
Int J Cancer; 1979 Feb; 23(2):245-52. PubMed ID: 83969
[TBL] [Abstract][Full Text] [Related]
2. Different expression of Lyt differentiation antigens and cell surface glycoproteins by a murine T lymphoma line and its highly metastatic variant.
Altevogt P; Kurnick JT; Kimura AK; Bosslet K; Schirrmacher V
Eur J Immunol; 1982 Apr; 12(4):300-7. PubMed ID: 6124426
[TBL] [Abstract][Full Text] [Related]
3. Antigenic variation in cancer metastasis: immune escape versus immune control.
Schirrmacher V; Fogel M; Russmann E; Bosslet K; Altevogt P; Beck L
Cancer Metastasis Rev; 1982; 1(3):241-74. PubMed ID: 6985248
[TBL] [Abstract][Full Text] [Related]
4. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective anti-tumor immunity in vivo and of cytolytic T cells in vitro.
Bosslet K; Schirrmacher V; Shantz G
Int J Cancer; 1979 Sep; 24(3):303-13. PubMed ID: 314938
[No Abstract] [Full Text] [Related]
5. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. X. Immunoselection of tumor variants differing in tumor antigen expression and metastatic capacity.
Schirrmacher V; Bosslet K
Int J Cancer; 1980 Jun; 25(6):781-8. PubMed ID: 14768708
[TBL] [Abstract][Full Text] [Related]
6. Suggestive evidence that the highly metastatic variant ESb of the T-cell lymphoma Eb is derived from spontaneous fusion with a host macrophage.
Larizza L; Schirrmacher V; Graf L; Pflüger E; Peres-Martinez M; Stöhr M
Int J Cancer; 1984 Nov; 34(5):699-707. PubMed ID: 6500746
[TBL] [Abstract][Full Text] [Related]
7. New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells.
von Hoegen P; Altevogt P; Schirrmacher V
Cell Immunol; 1987 Oct; 109(2):338-48. PubMed ID: 3117377
[TBL] [Abstract][Full Text] [Related]
8. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
Weinhold KJ; Wheelock EF
Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
Fuyama S; Yamamoto H; Fujii Y; Arai S
Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
[TBL] [Abstract][Full Text] [Related]
10. Analysis of protective and cytotoxic immune responses in vivo against metabolically inactivated and untreated cells of a mutagenized tumor line (requirements for tumor immunogenicity).
Wehrmaker A; Lehmann V; Dröge W
Cell Immunol; 1986 Sep; 101(2):290-8. PubMed ID: 2428514
[TBL] [Abstract][Full Text] [Related]
11. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. V. Transfer of protective immunity with H-2 identical immune T cells from B10.D2 mice.
Schirrmacher V
Int J Cancer; 1979 Jul; 24(1):80-6. PubMed ID: 314423
[No Abstract] [Full Text] [Related]
12. In vitro reactivity of splenic lymphocytes from normal and UV-irradiated mice against syngeneic UV-induced tumors.
Fortner GW; Kripke ML
J Immunol; 1977 Apr; 118(4):1483-7. PubMed ID: 66296
[TBL] [Abstract][Full Text] [Related]
13. Cell-mediated immunity to leukemia virus- and tumor-associated antigens in mice.
Herberman RB; Holden HT; Ting CC; Lavrin DL; Kirchner H
Cancer Res; 1976 Feb; 36(2 pt 2):615-21. PubMed ID: 56223
[TBL] [Abstract][Full Text] [Related]
14. Resistance of metastatic tumor variants to tumor-specific cytotoxic T-lymphocytes not due to defects in expression of restricting major histocompatibility complex molecules in murine cells.
Altevogt P; Leidig S; Heckl-Oestreicher B
Cancer Res; 1984 Nov; 44(11):5305-13. PubMed ID: 6333273
[TBL] [Abstract][Full Text] [Related]
15. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
16. Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cells.
Zangemeister-Wittke U; Schirrmacher V
Biotherapy; 1991; 3(4):319-29. PubMed ID: 1786195
[TBL] [Abstract][Full Text] [Related]
17. Modification of tumor cells by a low dose of Newcastle disease virus. Augmentation of the tumor-specific T cell response in the absence of an anti-viral response.
Von Hoegen P; Weber E; Schirrmacher V
Eur J Immunol; 1988 Aug; 18(8):1159-66. PubMed ID: 2970967
[TBL] [Abstract][Full Text] [Related]
18. Studies on the induction and expression of T cell-mediated immunity. IV. Non-overlapping populations of alloimmune cytotoxic lymphocytes with specificity for tumor-associated antigens and transplantation antigens.
Kedar E; Bonavida B
J Immunol; 1975 Nov; 115(5):1301-8. PubMed ID: 51889
[TBL] [Abstract][Full Text] [Related]
19. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. I. Preferential reactivity of in vitro generated secondary CTL with syngeneic tumor cells.
Plata F; Jongeneel V; Cerottini JC; Brunner KT
Eur J Immunol; 1976 Nov; 6(11):823-9. PubMed ID: 187429
[TBL] [Abstract][Full Text] [Related]
20. Secondary cell-mediated cytotoxic response to challenge of rats with syngeneic Gross virus-induced lymphoma.
Glaser M; Herberman R
J Natl Cancer Inst; 1976 Jun; 56(6):1211-5. PubMed ID: 62841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
